{"id":3209,"date":"2026-07-29T21:00:00","date_gmt":"2026-07-29T21:00:00","guid":{"rendered":"https:\/\/futurenews24.com\/index.php\/2026\/07\/29\/utm_campaignrss-28\/"},"modified":"2026-08-03T00:59:28","modified_gmt":"2026-08-03T00:59:28","slug":"utm_campaignrss-28","status":"publish","type":"post","link":"https:\/\/futurenews24.com\/index.php\/2026\/07\/29\/utm_campaignrss-28\/","title":{"rendered":"Latigo posts outcomes on competitor to Vertex non-opioid ache reliever"},"content":{"rendered":"<p><br \/>\n<\/p>\n<div>\n<p class=\"wp-block-paragraph\">For many years, efforts to develop non-opioid ache medication had been marked by failure. However what was as soon as a graveyard of drug discovery is rapidly turning right into a race for a multibillion-dollar market, with Latigo Biotherapeutics publishing optimistic knowledge on Wednesday for a remedy meant to rival a Vertex drugs already in the marketplace.<\/p>\n<p class=\"wp-block-paragraph\">The startup\u2019s Part 2 trial enrolled 343 sufferers who\u2019d gotten tummy tuck surgical procedure; they had been randomized to obtain a excessive or low dose of Latigo\u2019s experimental tablet, a placebo, or a mix of acetaminophen and the opioid hydrocodone. These given both dose of Latigo\u2019s oral drug, LTG-001, confirmed statistically vital ache aid in comparison with placebo after 48 hours. And whereas members in all teams had the choice to make use of the opioid oxycodone in the event that they wanted further ache administration, these on a excessive dose of Latigo\u2019s remedy had been considerably much less probably to take action than members on placebo.<\/p>\n<p class=\"wp-block-paragraph\">The drug was typically protected and effectively tolerated, with greater general opposed occasion charges within the placebo group than in both remedy group. Some opposed occasions, nevertheless, had been extra widespread within the remedy teams: 7% of these taking a excessive dose of LTG-001 had a fever, in contrast with 2% of individuals on placebo, and 6% skilled lightheadedness, in contrast with 1% of the placebo group.\u00a0<\/p>\n<div class=\"restricted-content-breaker article\" aria-labelledby=\"restricted-story-heading\" aria-describedby=\"restricted-story-description\" checked=\"false\">\n<div class=\"restricted-content-breaker-bar\">\n<p class=\"restricted-text\">STAT+ Unique Story<\/p>\n<p class=\"restricted-login\">Have already got an account? Log in<\/p>\n<\/p><\/div>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<div class=\"restricted-content-breaker-wrapper\">\n\t\t\t\t<span class=\"stat-paywall-archive\"><\/p>\n<p>\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t<\/span><\/p>\n<h2 id=\"restricted-story-heading\">This text is unique to STAT+ subscribers<\/h2>\n<h3 id=\"restricted-story-description\">Unlock this text \u2014 plus day by day protection and evaluation of the biotech sector \u2014 by subscribing to STAT+.<\/h3>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Have already got an account? Log in<\/p>\n<div class=\"restricted-content-breaker-cards\">\n<div class=\"slider-container\" aria-label=\"Subscription plan toggle\">\n\t\t\t\t\t\tParticular person plans<\/p>\n<p>\t\t\t\t\t\tGroup plans\n\t\t\t\t\t<\/p><\/div><\/div>\n<p>\t\t\t\tView All Plans\n\t\t\t<\/p><\/div><\/div>\n<div class=\"restricted-message-breaker\">\n<div class=\"restricted-content-wrapper\">\n<div class=\"restricted-content-message\">\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo learn the remainder of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\tSubscribe\n\t\t\t\t\t\t\t\t\t<\/p><\/div><\/div><\/div><\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.statnews.com\/2026\/07\/29\/latigo-phase-2-results-non-opioid-pain-reliever-ltg-001\/?utm_campaign=rss\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>For many years, efforts to develop non-opioid ache medication had been marked by failure. However what was as soon as a graveyard of drug discovery is rapidly turning right into a race for a multibillion-dollar market, with Latigo Biotherapeutics publishing optimistic knowledge on Wednesday for a remedy meant to rival a Vertex drugs already in [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3211,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/www.statnews.com\/wp-content\/uploads\/2026\/07\/AdobeStock_613796267-1024x576.jpeg","fifu_image_alt":"","jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_override_bookmark_settings":[],"jnews_social_meta":[],"jnews_override_counter":[],"footnotes":""},"categories":[10],"tags":[3612,3610,3613,3614,3611,3615,3506,2425],"class_list":["post-3209","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology","tag-competitor","tag-latigo","tag-nonopioid","tag-pain","tag-posts","tag-reliever","tag-results","tag-vertex"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Latigo posts outcomes on competitor to Vertex non-opioid ache reliever - Future News 24<\/title>\n<meta name=\"description\" content=\"Latigo Biotherapeutics said LTG-001 was safe and produced statistically significant pain relief. A Phase 3 trial will start this year.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/futurenews24.com\/index.php\/2026\/07\/29\/utm_campaignrss-28\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Latigo posts outcomes on competitor to Vertex non-opioid ache reliever - Future News 24\" \/>\n<meta property=\"og:description\" content=\"Latigo Biotherapeutics said LTG-001 was safe and produced statistically significant pain relief. A Phase 3 trial will start this year.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/futurenews24.com\/index.php\/2026\/07\/29\/utm_campaignrss-28\/\" \/>\n<meta property=\"og:site_name\" content=\"Future News 24\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-29T21:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-03T00:59:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.statnews.com\/wp-content\/uploads\/2026\/07\/AdobeStock_613796267-1024x576.jpeg\" \/>\n<meta name=\"author\" content=\"Future News 24\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.statnews.com\/wp-content\/uploads\/2026\/07\/AdobeStock_613796267-1024x576.jpeg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Future News 24\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/29\\\/utm_campaignrss-28\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/29\\\/utm_campaignrss-28\\\/\"},\"author\":{\"name\":\"Future News 24\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/person\\\/cecad1bde21cfc357cf70128144d6c83\"},\"headline\":\"Latigo posts outcomes on competitor to Vertex non-opioid ache reliever\",\"datePublished\":\"2026-07-29T21:00:00+00:00\",\"dateModified\":\"2026-08-03T00:59:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/29\\\/utm_campaignrss-28\\\/\"},\"wordCount\":304,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/29\\\/utm_campaignrss-28\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.statnews.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/AdobeStock_613796267-1024x576.jpeg\",\"keywords\":[\"competitor\",\"Latigo\",\"nonopioid\",\"pain\",\"posts\",\"reliever\",\"results\",\"Vertex\"],\"articleSection\":[\"BioTechnology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/29\\\/utm_campaignrss-28\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/29\\\/utm_campaignrss-28\\\/\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/29\\\/utm_campaignrss-28\\\/\",\"name\":\"Latigo posts outcomes on competitor to Vertex non-opioid ache reliever - Future News 24\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/29\\\/utm_campaignrss-28\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/29\\\/utm_campaignrss-28\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.statnews.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/AdobeStock_613796267-1024x576.jpeg\",\"datePublished\":\"2026-07-29T21:00:00+00:00\",\"dateModified\":\"2026-08-03T00:59:28+00:00\",\"description\":\"Latigo Biotherapeutics said LTG-001 was safe and produced statistically significant pain relief. A Phase 3 trial will start this year.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/29\\\/utm_campaignrss-28\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/29\\\/utm_campaignrss-28\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/29\\\/utm_campaignrss-28\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.statnews.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/AdobeStock_613796267-1024x576.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.statnews.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/AdobeStock_613796267-1024x576.jpeg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/29\\\/utm_campaignrss-28\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/futurenews24.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Latigo posts outcomes on competitor to Vertex non-opioid ache reliever\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#website\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/\",\"name\":\"Future News 24\",\"description\":\"The Smart Hub for AI and Next-Gen Innovation\",\"publisher\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/futurenews24.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\",\"name\":\"Future News 24\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/fn24-favicon.png\",\"contentUrl\":\"https:\\\/\\\/futurenews24.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/fn24-favicon.png\",\"width\":250,\"height\":250,\"caption\":\"Future News 24\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/person\\\/cecad1bde21cfc357cf70128144d6c83\",\"name\":\"Future News 24\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"caption\":\"Future News 24\"},\"sameAs\":[\"https:\\\/\\\/futurenews24.com\"],\"url\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/author\\\/mridulpahuja20\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Latigo posts outcomes on competitor to Vertex non-opioid ache reliever - Future News 24","description":"Latigo Biotherapeutics said LTG-001 was safe and produced statistically significant pain relief. A Phase 3 trial will start this year.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/futurenews24.com\/index.php\/2026\/07\/29\/utm_campaignrss-28\/","og_locale":"en_US","og_type":"article","og_title":"Latigo posts outcomes on competitor to Vertex non-opioid ache reliever - Future News 24","og_description":"Latigo Biotherapeutics said LTG-001 was safe and produced statistically significant pain relief. A Phase 3 trial will start this year.","og_url":"https:\/\/futurenews24.com\/index.php\/2026\/07\/29\/utm_campaignrss-28\/","og_site_name":"Future News 24","article_published_time":"2026-07-29T21:00:00+00:00","article_modified_time":"2026-08-03T00:59:28+00:00","og_image":[{"url":"https:\/\/www.statnews.com\/wp-content\/uploads\/2026\/07\/AdobeStock_613796267-1024x576.jpeg","type":"","width":"","height":""}],"author":"Future News 24","twitter_card":"summary_large_image","twitter_image":"https:\/\/www.statnews.com\/wp-content\/uploads\/2026\/07\/AdobeStock_613796267-1024x576.jpeg","twitter_misc":{"Written by":"Future News 24","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/29\/utm_campaignrss-28\/#article","isPartOf":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/29\/utm_campaignrss-28\/"},"author":{"name":"Future News 24","@id":"https:\/\/futurenews24.com\/#\/schema\/person\/cecad1bde21cfc357cf70128144d6c83"},"headline":"Latigo posts outcomes on competitor to Vertex non-opioid ache reliever","datePublished":"2026-07-29T21:00:00+00:00","dateModified":"2026-08-03T00:59:28+00:00","mainEntityOfPage":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/29\/utm_campaignrss-28\/"},"wordCount":304,"commentCount":0,"publisher":{"@id":"https:\/\/futurenews24.com\/#organization"},"image":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/29\/utm_campaignrss-28\/#primaryimage"},"thumbnailUrl":"https:\/\/www.statnews.com\/wp-content\/uploads\/2026\/07\/AdobeStock_613796267-1024x576.jpeg","keywords":["competitor","Latigo","nonopioid","pain","posts","reliever","results","Vertex"],"articleSection":["BioTechnology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/futurenews24.com\/index.php\/2026\/07\/29\/utm_campaignrss-28\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/29\/utm_campaignrss-28\/","url":"https:\/\/futurenews24.com\/index.php\/2026\/07\/29\/utm_campaignrss-28\/","name":"Latigo posts outcomes on competitor to Vertex non-opioid ache reliever - Future News 24","isPartOf":{"@id":"https:\/\/futurenews24.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/29\/utm_campaignrss-28\/#primaryimage"},"image":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/29\/utm_campaignrss-28\/#primaryimage"},"thumbnailUrl":"https:\/\/www.statnews.com\/wp-content\/uploads\/2026\/07\/AdobeStock_613796267-1024x576.jpeg","datePublished":"2026-07-29T21:00:00+00:00","dateModified":"2026-08-03T00:59:28+00:00","description":"Latigo Biotherapeutics said LTG-001 was safe and produced statistically significant pain relief. A Phase 3 trial will start this year.","breadcrumb":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/29\/utm_campaignrss-28\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/futurenews24.com\/index.php\/2026\/07\/29\/utm_campaignrss-28\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/29\/utm_campaignrss-28\/#primaryimage","url":"https:\/\/www.statnews.com\/wp-content\/uploads\/2026\/07\/AdobeStock_613796267-1024x576.jpeg","contentUrl":"https:\/\/www.statnews.com\/wp-content\/uploads\/2026\/07\/AdobeStock_613796267-1024x576.jpeg"},{"@type":"BreadcrumbList","@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/29\/utm_campaignrss-28\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/futurenews24.com\/"},{"@type":"ListItem","position":2,"name":"Latigo posts outcomes on competitor to Vertex non-opioid ache reliever"}]},{"@type":"WebSite","@id":"https:\/\/futurenews24.com\/#website","url":"https:\/\/futurenews24.com\/","name":"Future News 24","description":"The Smart Hub for AI and Next-Gen Innovation","publisher":{"@id":"https:\/\/futurenews24.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/futurenews24.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/futurenews24.com\/#organization","name":"Future News 24","url":"https:\/\/futurenews24.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/futurenews24.com\/#\/schema\/logo\/image\/","url":"https:\/\/futurenews24.com\/wp-content\/uploads\/2026\/06\/fn24-favicon.png","contentUrl":"https:\/\/futurenews24.com\/wp-content\/uploads\/2026\/06\/fn24-favicon.png","width":250,"height":250,"caption":"Future News 24"},"image":{"@id":"https:\/\/futurenews24.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/futurenews24.com\/#\/schema\/person\/cecad1bde21cfc357cf70128144d6c83","name":"Future News 24","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","caption":"Future News 24"},"sameAs":["https:\/\/futurenews24.com"],"url":"https:\/\/futurenews24.com\/index.php\/author\/mridulpahuja20\/"}]}},"_links":{"self":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/3209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/comments?post=3209"}],"version-history":[{"count":1,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/3209\/revisions"}],"predecessor-version":[{"id":3210,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/3209\/revisions\/3210"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/media\/3211"}],"wp:attachment":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/media?parent=3209"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/categories?post=3209"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/tags?post=3209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}